Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/10—Dispersions; Emulsions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/4164—1,3-Diazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
  • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
  • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
  • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
  • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/10—Antimycotics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
  • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
  • A61B17/42—Gynaecological or obstetrical instruments or methods
  • A61B2017/4216—Operations on uterus, e.g. endometrium

Definitions

• the present invention relates to a delivery system including an applicator that demonstrates controlled release of active agents, that has a high internal phase ratio value, and that is suitable for use in the vaginal cavity.
• Medical treatment of the female reproductive system for the prevention, control, diagnosis, and cure of disease typically involves the delivery of pharmaceutically active agents to the vaginal cavity and proximal organs.
• agents are put in the form of gels, foams, creams, suppositories, and dissolving tablets, or other forms generally known in the art.
• these forms of delivery have not demonstrated the ability to deliver active agents to the vaginal cavity in a controlled manner, particularly for periods of three hours or longer, while providing a high level of bioadherence and a high level of stability in environments having either high or low temperatures.
• the vaginal cavity exhibits an aqueous environment, with fluids having a pH in the range of 4.5 to 5.5 and an internal temperature of approximately 98.6°F (37°C).
• the environment of the vaginal cavity is also conducive to the growth of microorganisms, such as bacteria and fungi, including yeast, and the retention of foreign particulates, such as seminal fluid resulting from intercourse, and menstrual debris.
• the vaginal cavity is also characterized by the ability for considerable physical deformation, such as that resulting from sexual intercourse or insertion of tampons.
• Agents such as fungicides, have typically been used to treat ailments and afflictions in the vaginal cavity.
• the pharmaceutical and chemical activity of these agents has not reached an optimal level of effectiveness. This limitation in effectiveness is due, in part or in whole, to the inadequacy of the currently available agents
• STLDOl-1085330-1 delivery systems have not sr ability to release a pharmaceutically active agent in an optimally safe manner for periods of three hours or greater, without encountering problems related to bioadherence or excessive release of the active pharmaceutical ingredient.
• delivery systems that are available generally begin to either solubilize, disperse or liquify almost immediately following insertion into the vaginal cavity. Thus, these delivery systems typically have minimal bioadherence to the vaginal walls.
• STLDO1-108533O-1 for a controlled release delivery system providing optimal treatment of vagin ⁇ ailments and afflictions. Accordingly, there is an unmet need for a delivery system providing a consistent release of a pharmaceutically active agent to the vaginal cavity, specifically a system allowing pharmaceutical activity for an extended period of time, such as at least three hours, and providing high levels of bioadherence. Furthermore, there is an unmet need in the art for a delivery system that reduces the proportion of propylene glycol in the formulation.
• a first embodiment of the present invention provides a delivery system for the treatment of fungal infections of the human female vaginal cavity comprising an effective amount of imidazole derivative active agent and one or more pharmaceutically acceptable excipients which allow the active agent to be released in a controlled manner to a site in the vaginal cavity, wherein the delivery system has an internal phase emulsion ratio of greater than 70%.
• a second embodiment of the present invention is a method of treating a vaginal fungal infection in a female human, comprising administering to the vaginal cavity a delivery system having an effective amount of an imidazole derivative active agent and one or more pharmaceutically acceptable excipients which allow the active agent to be released in a controlled manner to a site in the vaginal cavity, wherein the delivery system has an internal phase emulsion ratio of greater than 70%.
• the delivery system comprises a compact, prefilled, ready- to-use, applicator for dispensing a medicament to a body cavity
• a body cavity includes an elongated body having a proximal dispensing end and a distal grasping end.
• the body is of a sufficient length to dispense medicament to a desired location within a selected body cavity.
• a proximal portion of the elongated body forms a reservoir adapted to contain a predetermined amount of medicament.
• a distal portion of the elongated body forms a plunger housing.
• Closure means are disposed at the dispensing end of the reservoir,
• STLDO1 -1O8533O-1 and impeller means are disposed at its distal end, at the junction of the reserve plunger assembly housing.
• a telescoping plunger rod assembly having stop means associated therewith for limiting telescopic extension and preventing telescopic collapse of the plunger rod assembly, is connected to the impeller means.
• Grasping means are provided for operating said telescoping plunger rod assembly. The applicator is operated by holding it at the grasping end and inserting it, closure end first, into the desired cavity. The plunger assembly is drawn back via the grasping means to the limit of the stop means, and then the plunger assembly is pushed proximally relative to the elongated body, thereby creating pressure to open the closure member and dispense the medicament from the reservoir
• FIG. 1 is a side elevational view of a medicament applicator illustrating the principles of the present invention, shown in the compact, ready-to-use position;
• FIG. 2 is an exploded view of the medicament applicator of FIG. 1, showing a closure portion, a cylindrical body portion, a first plunger member and second plunger member (together forming a plunger assembly), and a grasping member;
• a medicament applicator 20 has a dispensing end 22 and a grasping end 24.
• a cylindrical member 26 serves as the main body of the applicator, having a medicament reservoir portion, a plunger assembly housing portion, and a grasping surface portion 32.
• a closure member 34 is slidingly received over a reduced outer diameter portion 36 of the cylindrical member 26.
• a plunger assembly 38 having a first plunger member 40 with a piston portion 42 and a second plunger member 44, is slidingly received within cylindrical member 26; the piston portion 42 being disposed within the medicament reservoir portion 28 and the rest of
• the present invention provides a delivery system that has a high internal emulsion ratio between 70% to 90%, preferably wherein the nonlipoidal phases comprise from about 70% to 90% by volume of the system.
• the formulations of the present invention reduce the amount of propylene glycol by about 20% to about 80%, preferably about 25%, compared to the formulations in the prior art, while still maintaining the same high internal emulsion ratio of 70% to 90%.
• the present invention can sustain a temperature of 86°F for at least one month, preferably greater than one month, more preferably greater than two months, more preferably greater than six months, and more preferably greater than one year, for example three to five years.
• the increased stability allows the present invention to be stored in environments susceptible to climate changes or temperature extremes. This improvement is generally known as "improved shelf life.”
• This invention provides a delivery system for the vaginal cavity, wherein the system delivers pharmaceutically active agents to the vaginal cavity in a controlled manner over an extended period of time.
• the extended period of time is at least three hours, and in most cases, the period of time can last as long as ten days or more.
• the delivery system is characterized by a high internal emulsion ratio.
• the delivery system is preferably an emulsion comprised of at least 70% hydrophilic constituents by volume of the system.
• the delivery system provides agents that restore, maintain, and cure ailments or afflictions affecting the vaginal cavity.
• the "vaginal cavity” also includes proximal areas, e.g., it includes the vagina, female urinary tract, such as the ostium of the urethra, organs and tissues at the opening of the vaginal cavity, as well as reproductive organs accessible through the cavity.
• the delivery system is also characterized by a capability to adhere (otherwise known as "bioadhere") to the walls of the vaginal cavity and proximal areas, including epithelial cells, tissue and organs.
• the delivery system not only releases an active agent, but it releases the agent in a controlled manner to obtain optimal absorption.
• the active agent is made available for absorption, pharmacological or other effect at a site of absorption or action in an amount sufficient to cause a desired response consistent with the intrinsic
• the delivery system of the present invention is preferably characterized by the controlled release of the active agent to a receptor site, site of action, site of absorption, or site of use and the achievement of the desired effect at that site.
• the delivery system is preferably not miscible in water and is not harmful for use in the vaginal cavity.
• the delivery system of the present invention can comprise a combination of active and non-active pharmaceutical ingredients (also known generally herein as "excipients").
• Non-active ingredients serve to solubilize, suspend, thicken, dilute, emulsify, stabilize, preserve, protect, color, flavor, and fashion the active ingredients into an applicable and efficacious preparation that is safe, convenient, and otherwise acceptable for use.
• Active ingredients which, for example, can constitute 1.0% to 10% of the total weight percent of the delivery system, preferably from about 1.5% to 2.5%, more preferably about 2.0%, provide medicinal or chemical treatment of the vaginal cavity. These active ingredients are formulated to be released in a controlled manner.
• Active ingredients comprising the active agent may be any of those ingredients that are approved for or are used for the treatment, prophylaxis, cure, or mitigation of any disease of the vaginal cavity.
• the primary active ingredients of the delivery system of the present invention are imidazole derivatives, which are antifungal and antibacterial in nature.
• the imidazole derivatives may be present in the form of pharmaceutically acceptable salts or nitrates. Examples of imidazole derivatives that can be used in this invention include miconazole nitrate, butoconazole nitrate, oxiconazole nitrate, metronidazole nitrate, terconazole nitrate, and clotrimazole nitrate, among others known in the art.
• a preferred imidazole derivative in the delivery system of the present invention is butoconazole nitrate.
• the delivery system can be comprised of unit cells. These unit cells are the basic, nondivisable, repeating unit of the systems.
• the unit cells have internal and external phases, which respectively represent the internal and external phases of the delivery system.
• the internal phase may be nonlipoidal, i.e., miscible with water, and may comprise water, glycerine, or combinations thereof.
• the internal phase may be multiphasic and may be a solution, suspension, emulsion, or combination thereof, and
• STLD01 -1O8533O-1 6 may contain at least a portion of the active agent.
• the external phase may be continuous phase and lipoidal, i.e., containing organic compounds comprising the neutral fats, fatty acids, waxes, phosphatides, petrolatum, fatty acid esters of monoprotic alcohols and mineral oils that are insoluble in water but soluble in alcohol, ether, chloroform or other fat solvents.
• the delivery system may be classified conventionally, for example, as emulsions, emulsions/dispersions, double emulsions, suspensions within emulsions, suppositories, foams, or another classification known in the art. Accordingly, in embodiments of the invention, the delivery systems can vary in form. In one embodiment of the present invention, the system is an emulsification of ingredients in a cream form. Other embodiments of the present invention include lotions, gels, foams, and various emulsifications. Additionally, other embodiments of the present invention include liquids, semi-solids and solids having a viscosity range from about 5,000 to 750,000 centipoise, preferably 350,000 to 550,000 centipoise. Optimizing viscosity can allow the system of delivery to achieve maximum bioadherence on the vaginal cavity.
• the delivery system is preferably in the form of an emulsion of medium or high internal phase ratio, which is the ratio between the external phase and the internal phase.
• the ratio value represents how much the internal phase comprises of the system in terms of percent by volume of the system.
• the ratio can be at least 70% by volume, preferably at least 75%, more preferably at least 80% and even more preferably up to about 90%.
• the controlled release feature of the present invention is a product of the high internal phase emulsion exhibited by the present invention.
• Emulsifiers, auxiliary agents, emulsifying agents or other excipients such as glycerol monostearate, glycerol monoisostearate, methylparaben, propylparaben, and generally oils, glycerides, sucrose esters, sorbitan esters, polysorbates, stearoyl lactylates, lecithin and other like compounds, create emulsified globules comprised of non-active ingredients.
• the globules contain reservoirs of the active agents.
• globules slowly disperse upon application, i.e., the globules tend to seek the containing surfaces or membranes, and the globules spread locally (i.e., in the vaginal cavity), thereby forming a "film" containing globules that releases the active agent, in a
• STLDO1-1O8533O-1 7 controlled release fashion, over time. This process occurs over a period of tin as, for example, three hours to up to ten days or more, and is therefore generally known as "controlled release.”
• the bioadherence feature of the present invention is a product of the high internal phase emulsion exhibited by the present invention.
• the emulsified globules which are comprised of excipients (examples of which are listed above), are small in volume, but have a relatively high surface area. The surface area and nature of the surfaces allows the globules to interact with human tissue through a number of physical binding molecular forces such as Van der Waals forces or hydrogen bonding. These binding forces are intensified due to the high internal phase ratio of the emulsion, there being such a large number of these very small globules as compared to the small volume of the continuous or external phase comprising the emulsion.
• Propylene glycol can affect the stability and diffusion rate of the delivery system.
• Propylene glycol can be included in the formulation of the delivery system to serve as a solvent that helps to dissolve the active ingredient of the delivery system, e.g., the imidazole, such as butoconazole nitrate. It has been known in conventional formulations to use propylene glycol at 5.00 weight percent.
• the propylene glycol can be present in an amount from about 1.0 to about 4.0 weight percent, more preferably from about 3.5 to about 3.85 weight percent, and most preferably about 3.75 weight percent, i.e., the amount of propylene glycol is reduced by about 25% as compared to the 5.00 weight percent believed to be required in prior delivery systems.
• the delivery system of at least some embodiments of the present invention improves upon the delivery systems known in the art by reducing the amount of propylene glycol in the formulation.
• the reduction of propylene glycol does not affect the internal phase emulsion ratio, which is greater than 70%, nor does it
• STLDO1 -1O8533O-1 o preclude the formation of an emulsion. Moreover, the reduction of propylen used achieves unexpected results that are highly advantageous and beneficial to the pharmaceutical and medicinal arts.
• the delivery system of the present invention overcomes the limitations of the prior art. For example, reducing the amount of propylene glycol improves the diffusion rate of the active pharmaceutical agent in the delivery system while maintaining its beneficial pharmaceutical properties and effectiveness.
• the delivery system of embodiments of the present invention has demonstrated physical attributes such as bioadherence and potentially increased physical stability in relation to phase separation and the ability to remain in place resisting dispersion for extended periods of time.
• the overall increased physical attributes of the delivery system of the present invention provides a more effective product for the consumer and a more optimal treatment in the vaginal cavity, i.e., the emulsion is stable and has improved control over diffusion rates of the active pharmaceutical ingredient thus is more effective.
• the increased stability provides increased shelf life in areas where temperatures may be uncontrolled, further allowing the delivery system to be used by a greater number of people.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Chemical & Material Sciences (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Engineering & Computer Science (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Epidemiology (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Organic Chemistry (AREA)
• Communicable Diseases (AREA)
• Heart & Thoracic Surgery (AREA)
• Reproductive Health (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Oncology (AREA)
• Anesthesiology (AREA)
• Biomedical Technology (AREA)
• Gynecology & Obstetrics (AREA)
• Hematology (AREA)
• Dispersion Chemistry (AREA)
• Urology & Nephrology (AREA)
• Endocrinology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)
• Infusion, Injection, And Reservoir Apparatuses (AREA)

Priority Applications (22)

Applications Claiming Priority (2)

Publications (1)

Family

ID=35787422

Family Applications (2)

Family Applications After (1)

Country Status (13)

Cited By (2)

Families Citing this family (7)

Citations (2)

Family Cites Families (4)

• 2004
  • 2004-07-08 MX MXPA04007681A patent/MXPA04007681A/es unknown
  • 2004-07-08 WO PCT/US2004/022058 patent/WO2006016869A1/en active Application Filing
  • 2004-08-03 CZ CZ200415701U patent/CZ15068U1/cs not_active IP Right Cessation
  • 2004-09-06 NL NL1026978A patent/NL1026978C1/nl not_active IP Right Cessation
  • 2004-09-09 ES ES200402091U patent/ES1060042Y/es not_active Expired - Fee Related
  • 2004-09-15 AU AU2004100776A patent/AU2004100776A4/en not_active Expired
  • 2004-12-22 FR FR0413770A patent/FR2872702B3/fr not_active Expired - Lifetime
• 2005
  • 2005-07-08 CA CA002572919A patent/CA2572919A1/en not_active Abandoned
  • 2005-07-08 NZ NZ552406A patent/NZ552406A/en not_active IP Right Cessation
  • 2005-07-08 RU RU2007104782/14A patent/RU2379027C2/ru not_active IP Right Cessation
  • 2005-07-08 EP EP05769226A patent/EP1765452A4/en not_active Withdrawn
  • 2005-07-08 WO PCT/US2005/024200 patent/WO2006014572A1/en active Application Filing
  • 2005-07-08 AU AU2005269844A patent/AU2005269844A1/en not_active Abandoned
  • 2005-07-08 MX MX2007000109A patent/MX2007000109A/es active IP Right Grant
  • 2005-07-08 BR BRPI0513066-2A patent/BRPI0513066A/pt not_active IP Right Cessation
  • 2005-07-08 CN CN2011101190673A patent/CN102188375A/zh active Pending
  • 2005-07-08 CN CNA2005800002434A patent/CN1771023A/zh active Pending

Patent Citations (2)

Also Published As

Similar Documents

Legal Events